6 / 14
Volume 8
Journal of Biotechnology & Biomaterials
ISSN: 2155-952X
Biotech Congress 2018 & Enzymology 2018
March 05-07, 2018
Page 40
conference
series
.com
JOINT EVENT
20
th
Global Congress on
Biotechnology
3
rd
International Conference on
Enzymology and Molecular Biology
&
March 05-07, 2018 London, UK
Sergey Suchkov, J Biotechnol Biomater 2018, Volume 8
DOI: 10.4172/2155-952X-C2-090
Proteolytic abzymes as translational tools of the newest generation to be exploited for biodesign and
bioengineering
C
atalytic Abs (catAbs) are multivalent im-munoglobulins (Igs) with a capacity to hy-drolyze the antigenic (Ag) substrate. In
this sense, proteolytic Abs (Ab-proteases) repre-sents Abs to provide proteolytic effects. Abs against myelin basic protein/
MBP with pro-teolytic activity exhibiting sequence-specific cleavage of MBP is of great value to monitor demyelination whilst
in multiple sclerosis. The activity of Ab-proteases was first regis-tered at the subclinical stages, 1-2 years prior to the clinical
illness and the activity of the Ab-proteases revealed significant correlation with scales of demyelination and the disabil-ity of
the patients as well. So, the activity of Ab-proteases and its dynamics tested would confirm a high subclinical and predictive
(translational) value of the tools as applicable for personalizedmonitoring protocols. Ab-proteases directly affecting remodeling
of tissues with multilevel architectonics (for in-stance, myelin) are of tremendous value. By changing sequence specificity one
may reach reduction of a density of the negative proteo-lytic effects within the myelin sheath and thus minimizing scales of
demyelination. Ab-proteases can be programmed and re-programmed to suit the needs of the body metabolism or could be
designed for the de-velopment of new catalysts with no natural counterparts. Further studies are needed to secure artificial
or edited Ab-proteases as translational tools of the newest generation to diagnose, to monitor, to control and to treat and
rehabilitate multiple sclerosis patients at clinical stages and to prevent the disorder at subclinical stages in persons at risks.
Recent Publications
1. Gabibov A A, Paltsev M A and Suchkov S V (2011) Antibody-associated proteol-ysis in surveillance of autoimmune
de-myelination: clinical and preclinical is-sues. Future Neurology 6(3):303-305.
2. D Kostyushev, I Tsarev, D Gnatenko, M Paltsev and S Suchkov (2011) Myelin-associated serological targets as applica-
ble to diagnostic tools to be used at the preclinical and transient stages of multiple sclerosis progression. Open J
Immunology 1(3):80-86.
3. Gabibov A G, Ponomarenko N A, Tretyak E B, Paltsev M A and Suchkov S V (2006) Catalytic autoantibodies in clin-
ical autoimmunity and modern medicine. Autoimmunity Reviews 2006(5):324-330.
4. Ponomarenko N A, Durova OM, Voro-biev I I, Belogurov A A, Telegin G B, et al. (2005) Catalytic activity of autoanti-
bodies toward myelin basic protein corre-lates with the scores on the multiple scle-rosis expanded disability status
scale. Immunol. Lett. 103(1):45-50.
5. Ponomarenko N A, Durova O M, Voro-biev I I, Aleksandrova E S, Telegin G B, et al. (2002) Catalytic antibodies in
clini-cal and experimental pathology: human and mouse models. Journal of Immuno-logical Methods 2002(269):197-
211.
Sergey Suchkov
I M Sechenov First Moscow State Medical University, Russia